{
    "2020-10-20": [
        [
            {
                "time": "",
                "original_text": "丽珠试剂分拆上市冲击千亿蓝海、CRO第四家A+H企业将现……上市药企资本变局不断",
                "features": {
                    "keywords": [
                        "丽珠试剂",
                        "分拆上市",
                        "CRO",
                        "A+H企业",
                        "资本变局"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "智通AH统计|10月20日",
                "features": {
                    "keywords": [
                        "AH统计"
                    ],
                    "sentiment_score": 0.0,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "药企行贿案密集曝光，政策组合拳能斩断灰色利益链条吗？",
                "features": {
                    "keywords": [
                        "药企",
                        "行贿案",
                        "政策组合拳",
                        "灰色利益链条"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "药企行贿案密集曝光！灰色利益链还有多少生存空间？ 其他违规处罚",
                "features": {
                    "keywords": [
                        "药企",
                        "行贿案",
                        "灰色利益链",
                        "违规处罚"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "药企行贿案密集曝光：有院内人员收上千万回扣 其他违规处罚",
                "features": {
                    "keywords": [
                        "药企",
                        "行贿案",
                        "回扣",
                        "违规处罚"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}